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Objectives
The main objective of this project was to create an informative video about the relationship between Down Syndrome and leukemia, to explain the parents and relatives of the affected children the
genetic basis of both conditions. Since it has been oriented to a non-specialized public, it has been done in an understandable fashion for people without knowledge in genetics. The information is
supported with animation drawings that complement the explanation given.
Popularization interest
Although the presence of people with Down syndrome is very common, in our society many do not know the origin of this condition or certain pathologies that are associated, as is the case of
leukemia. Despite having been designed for a specific public, this video is divided in four parts that can serve as a source of information for any person interested. Hence, it can be used to
understand basic concepts of genetics, as well as to know genetic factors predisposing to and causing Down syndrome and leukemia.
Genetic predisposition to leukemia in Down Syndrome
DS children have a 500-fold increased risk to develop Acute myeloid leukemia (AML). Nearly 10% of DS newborns develop TMD in their
3 to 7 first days of life. TMD is a clonal pre-leukemia characterized for an accumulation of immature megakaryoblasts in fetal liver,
bone marrow and peripheral blood, and a decrease in the number of platelets and erythrocytes. TMD is a cooperative process
between trisomy 21 and mutations acquired in GATA1 gene.
Although it is not entirely clear, it is believed that the overexpression of some genes involved in haematopoiesis present in
chromosome 21 and the alterations caused by this extra chromosome originate an over-proliferation of hematopoietic stem cells
(HSC) and myeloid progenitors. This provokes an increase in the number of megakaryocyte-erythroid progenitors (Fig. 4).
In addition, fetal liver hematopoietic microenvironment favours the appearance and maintenance of mutations in GATA1. This gene
codifies for a zinc-finger DNA-binding transcription factor with a key role in erythrocyte and megakaryoblast differentiation (Fig. 5).
Mutations that originate TMD and AMKL are indels and point mutations in exons 2 and 3. They are N-terminal truncating mutations,
which prevents the synthesis of GATA1 and allows for the expression of the isoform GATA1s. It lacks the transactivation domain, so it
is less effective regulating differentiation of erythrocytes and megakaryoblasts.
Therefore, trisomy 21 and the presence of truncating mutations in GATA1 are enough and necessary for the development of TMD,
which normally reverts spontaneously within 3 months of life.
Transient myeloproliferative disorder (TMD) Acute megakaryoblastic leukemia (AMKL) 
20% of survivors end up developing AMKL within 5 years. It is ocasionated by the inadequate elimination of all
the blasts with trisomy 21 and mutated GATA1, and in them new mutations appear. Some studies using whole-
exome sequencing and whole-genome sequence showed that AMKL evolves thanks to additional mutations
in other genes. These include cohesin components, CTCF, epigenetic regulators such as EZH2 and KANSL1,
and common signaling pathways such as the JAK family kinases and multiple RAS pathway genes (Fig. 8).
Children with AMKL need chemotherapy treatment, but they usually respond quite well and present a high
survival rate (Fig. 7).
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Genetics Basic Concepts Down Syndrome Leukemia
Certain basic concepts of genetics considered necessary to fully understand the video
in its entirety have been explained. Some of those are the components of DNA, its
organization, the formation of proteins (Fig.1) and the process of differentiation.
A brief clinical introduction to Down Syndrome and the associated pathologies has
been carried out. Subsequently, the three main processes that originate trisomy 21
have been detailed: meiotic nondisjunction (Fig. 2), translocation and mosaicism.
What is cancer and the three types of genes whose alteration causes a carcinogenic
process have been described: oncogenes, tumor suppressor genes and DNA repair
genes. The concepts explained after that are the hematopoietic process, leukemia and
its four main types (Fig. 3).
Bibliographic
research
Software 
selection
Talk to
affected
families
Write the
script
Prepare 
the
pictures
Video 
production
Record the
audio
Video 
edition
KRITA
VIDEO CONTENT
https://www.youtube.com/watch?v=8u6LB9veuWM
Fig 1. Protein biosynthesis
Fig 2. Meiotic nondisjunction of chromosome 21 (normally in the
female gamete) originates DS on 95% of cases Fig 3. The hematopoietic process and the four main leukemia types
Fig 4. Effect of trisomy 21 in hematopoiesis Fig 5. Effect of the apparence of mutations in the GATA1 gene
Fig 6. AMKL is the M7- AML subtype and it is caused by the
accumulation of malignant megakaryoblasts in different tissues Fig 7. Transition from TMD to AMKL
Fig 8. Brief overview of TMD and AMKL
